29 results on '"West, Michael L."'
Search Results
2. Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease
3. Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry
4. Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
5. Initiation of pharmacologic chaperone therapy for Fabry disease in the Canadian Fabry Disease Initiative (CFDI) registry is not associated with reduction of kidney function
6. Retrospective review of recent ASA prescribing practices for primary prevention of major adverse cardiovascular events in the Canadian Fabry Disease Initiative cohort
7. FollowME Fabry Pathfinders Registry: Renal effectiveness in a cohort of patients on migalastat treatment for at least three years
8. Glycosphingolipid evaluation for Fabry disease patients receiving migalastat after switching from enzyme replacement therapy
9. Chest pain subtype prevalence in the British Columbia cohort of the Canadian Fabry Disease Initiative
10. Facilitating intrafamily communication to enable earlier diagnosis of Fabry disease in relatives: Expert opinion
11. Switch from enzyme replacement therapy to pharmacologic chaperone: Improvement in advanced Fabry nephropathy
12. Fabry disease biomarkers in patients switched from enzyme replacement therapy to migalastat oral chaperone therapy
13. Lentivirus-mediated gene therapy for Fabry disease
14. The spectrum of podocyte injury in later onset (LO) variants of Fabry disease (FD)
15. FollowME Fabry Pathfinders registry: Renal effectiveness in a multi-national, multi-center cohort of patients on migalastat treatment for at least three years
16. Clinical characteristics of female patients enrolled in the FollowME Fabry Pathfinders registry
17. Corrigendum to “Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing” [2021 Sep-Oct;134(1–2):117–131]
18. Long-term outcomes in patients with Fabry disease who were treated with agalsidase alfa for more than nineteen years: The Fabry Outcome Survey
19. Early therapy in Fabry disease: Outcomes from the Canadian Fabry Disease Initiative (CFDI) registry
20. Early initiation of agalsidase alfa treatment improves clinical outcomes in male patients with classical Fabry disease: A Fabry Outcome Survey (FOS) analysis
21. Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease
22. Additional file 1 of Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
23. Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing
24. The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process.
25. Primary Hyperoxaluria Type 1 (PH1) Presenting With End-Stage Kidney Disease and Cutaneous Manifestations in Adulthood: A Case Report.
26. ApoA4 Mutations Cause Autosomal Dominant Tubulointerstitial Kidney Disease with Medullary Amyloidosis
27. FollowME Fabry Pathfinders Registry: Renal Effectiveness in a Cohort of Patients on Migalastat Treatment for at Least Three Years
28. Renal ANCA+ Vasculitis Concurrent with Fabry Nephropathy: Coincidence or Complication?
29. Renal and multisystem effectiveness of 3.9 years of migalastat in a global real-world cohort: Results from the followME Fabry Pathfinders registry.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.